• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$90.53 $0.04 (0.04%)

REAL-TIME: Last trade at

Allergan, Inc.

NYSE:AGN

Sunshine Ahead For This 'Organic' Shadow Stock

9 Cash Laden Large Caps With Strong EPS Growth Trends

9 Cash-Hoarding Large Cap Stocks With Buy Or Better Ratings

NICE Rec for Allergan's Botox - Analyst Blog

Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN

Weekly CFO Sells Highlight: EL, ACTU, AGN, BCR, RHT, ZNGA

UK's NICE Backs Allergan's Botox For Some Migraine Sufferers

Medicis Outshines in 1Q - Analyst Blog

Allergan Gets Subpoena From Government Over Lap-Band System

Allergan Hits Estimates in Solid Quarter

Allergan 1Q Profit Rose 45% On Stronger Specialty Drug Sales

Allergan Beats on Revs, Misses on EPS - Analyst Blog

24/7 Wall St. Closing Bell (CHK, COP, RSH, STM, AIZ, ABX, MRO, MA, AGN, AUY, TWX, CLX, RDC, RRD, MSO

UPDATE: Allergan's Profit Rises 45% On Stronger Botox Sales

Earnings Preview: Allergan - Analyst Blog

Jobs, consumer data to take back focus

Botox For Migraines Yields 'Small To Modest' Benefit - Study

PSivida: Small Cap Ophthalmology Based Biotech Positioned For Long-term Growth

Map Pharmaceuticals Plans FDA Meeting To Discuss Manufacturing Issues

Why Spectrum Pharmaceuticals Sank

After Announcing Drug Failure, Spectrum Pharmaceuticals Says it Will Buy Rival Allos

UPDATE: Amid Setback, Spectrum Pharma To Buy Allos For $206 Million

Bad Clinical Trial Trumps Good Acquisition

Watson Continues with ANDA Filings - Analyst Blog

4-Star Stocks Poised to Pop: Allergan

Charting a Course to Profit

Upgrades & Downgrades: Sell Best Buy? Why You Could Do Worse

Watson Says Received Favorable Ruling Over Generic Sanctura XR

Wrinkled Bladder? There's a Drug for That!

3 Stocks to Get on Your Watchlist

UPDATE: Allergan: Studies Show Botox Treats Overactive Bladder

2nd UPDATE: Allergan Studies Botox For Bladder, Other Illnesses

MAP Confident In Levadex, Plans Swift Response To FDA

Map Pharmaceuticals Drops on Migraine Drug Rejection

Third Time's the Charm for This Small-Cap Buyout

What Allergan Does With Its Cash

Court Deals Blow to Botox Competitor - Analyst Blog

Solta Updates on Liposonix Launch - Analyst Blog

UPDATE: Allergan: Sales Of Botox Alternative Blocked For 10 Months

2nd UPDATE: US Court Blocks Sales Of Botox Alternative

See More Articles...